European Commission Approves brentuximab vedotin for treatment of adults with previously untreated systemic anaplastic large cell lymphoma

Approval of the use of brentuximab in combination with cyclophosphamide, doxorubicin and prednisone for this indication is based on results of the Phase 3 ECHELON-2 study, in which the combination was shown to improve progression-free survival vs CHOP chemotherapy.

Biospace Inc.